Literature DB >> 1990210

Monoclonal antibody GB3 defines a widespread defect of several basement membranes and a keratinocyte dysfunction in patients with lethal junctional epidermolysis bullosa.

P Verrando1, C Blanchet-Bardon, A Pisani, L Thomas, F Cambazard, R A Eady, O Schofield, J P Ortonne.   

Abstract

An antigen expressed at the dermal-epidermal junction as well as in some other human basement membranes (BM) has been detected by the use of a monoclonal antibody termed GB3. This antigen, synthesized by cultured normal human keratinocytes, has been identified as a 600-kilodalton glycoprotein different from other known components of BM. Using indirect immunofluorescence, GB3 was found to be not reactive with the epidermal BM in patients with lethal junctional epidermolysis bullosa. The present study demonstrates (by indirect immunofluorescence) that GB3 defines a widespread defect of several BM in these patients. Furthermore, it gives evidences for an intrinsic biologic defect of lethal junctional epidermolysis bullosa epidermal keratinocytes using in vitro culture of these cells. Whether the lack of GB3 reactivity is the consequence of a true absence of the antigen or an alteration of its molecular structure is not yet known. Nevertheless, GB3 is a useful probe for both rapid and prenatal diagnosis of lethal junctional epidermolysis bullosa, which will give new insights into the molecular comprehension of this disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990210

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  24 in total

1.  Lethal junctional epidermolysis bullosa with normal expression of BM 600 and antro-pyloric atresia: a new variant of junctional epidermolysis bullosa?

Authors:  J P Lacour; P Hoffman; F Bastiani-Griffet; P Boutte; A Pisani; J P Ortonne
Journal:  Eur J Pediatr       Date:  1992-04       Impact factor: 3.183

Review 2.  Epidermolysis bullosa: hereditary skin fragility diseases as paradigms in cell biology.

Authors:  R A Eady; M G Dunnill
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 3.  Cultured epithelial autografts: diving from surgery into matrix biology.

Authors:  M Raghunath; M Meuli
Journal:  Pediatr Surg Int       Date:  1997-09       Impact factor: 1.827

4.  Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa.

Authors:  B Gatalica; L Pulkkinen; K Li; K Kuokkanen; M Ryynänen; J A McGrath; J Uitto
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

5.  Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer.

Authors:  J Hao; L Jackson; R Calaluce; K McDaniel; B L Dalkin; R B Nagle
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

6.  A homozygous mutation in the integrin alpha6 gene in junctional epidermolysis bullosa with pyloric atresia.

Authors:  L Ruzzi; L Gagnoux-Palacios; M Pinola; S Belli; G Meneguzzi; M D'Alessio; G Zambruno
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

7.  Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse.

Authors:  H Xu; P Christmas; X R Wu; U M Wewer; E Engvall
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

Review 8.  The molecular basis for inherited bullous diseases.

Authors:  B P Korge; T Krieg
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

9.  Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice.

Authors:  Z Lazarova; C Yee; T Darling; R A Briggaman; K B Yancey
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

10.  Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease.

Authors:  N Domloge-Hultsch; W R Gammon; R A Briggaman; S G Gil; W G Carter; K B Yancey
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.